Ana Blatnik

Ana Blatnik
no.: 32428 source: ARIS

researcher – active in research organisation
Edit
Research activity

Code Science Field Subfield
3.04.00  Medical sciences  Oncology   
3.00.00  Medical sciences     
Bibliography Representative bibliographic units | Personal | COBISS+
source: COBISS
source: SICRIS
Evaluation (metodology)
Evaluation of bibliographic research performance indicators according to ARIS methodology
source: COBISS
source: ARIS
Points
406.35
A''
25.96
A'
135.28
A1/2
279.28
CI10
685
CImax
220
h10
12
A1
1.38
A3
0.13
Data for the last 5 years (citations for the last 10 years) on October 15, 2025; Data for score A3 calculation refer to period 2020-2024 (2022, 2023)
Data for ARIS tenders ( 23.05.2022 – Target research programmes, archive )
Citations Citations for bibliographic records in COBIB.SI that are linked to records in citation databases
source: WoS source: Scopus source: COBISS
Database Linked records Citations Pure citations Average pure citations
WoS 49  682  621  12.67 
Scopus 39  734  673  17.26 
Doctoral dissertations and other final papers Show
Obtaining results now
source: COBISS
Employments
source: ARIS
Type of employment Research org. Research group
Full time employment (100%, RD:20%)  Institute of Oncology Ljubljana  Department of research 
Research projects Legend
source: ARIS
no. Code Title Period Head
1. N1-0197  Improving breast cancer screening through dynamic big data analytics of Quantitative Imaging Biomarkers (QIB)   1/1/2021 - 12/31/2024  PhD Robert Jeraj   3,258 
2. V3-1911  Slovenian genome project   11/1/2019 - 10/31/2022  PhD Borut Peterlin   9,348 
3. V3-2032  The impact of COVID-19 on the cancer management in Slovenia   10/1/2020 - 9/30/2022  PhD Tina Žagar   2,246 
4. V3-1638  Development and implementation of personalised breast cancer risk evaluation tool for Slovenian population   10/1/2016 - 9/30/2019  PhD Vesna Zadnik   3,312 
ARIS research and infrastructure programmes Legend
source: ARIS
no. Code Title Period Head
1. P3-0429  Slovenian research programme for comprehensive cancer control SLORApro   1/1/2022 - 12/31/2027 PhD Vesna Zadnik   4,979 
2. P3-0289  Characteristics of Malignant Neoplasms Important for Diagnosis, Prognosis and Treatment Outcome   1/1/2019 - 12/31/2027 PhD Nikola Bešić   3,726 
3. P3-0352  Moderate and high cancer risk population:counseling, mutational screening and prevention strategies   1/1/2018 - 12/31/2027 PhD Janez Žgajnar   3,311 
We were not given permission by the researcher to publish data.
Confirmation required
Views history
Favourite